GANX - Gain Therapeutics, Inc. 0 WATCHERS

GANX touching $3.999 now, slow and steady and great support/resistance testing. Still a speculative play but think this goes large as more data comes out

GANX going brrrrr

Anyone else in GANX??

GT-02287 addresses multiple potential sources of Parkinson's ($GANX)

Careful about this one. Always check post history of commenters for GANX and you will find tons of bot accounts posting nothing about this stock.

Have a look at GANX. Not saying buy for the sake of buying, but look it up

Here is latest info including H.C. Wainwright update. Very interesting comments by him. Gain Therapeutics(GANX): Updated Analyst Reports with All Eyes on Biomarker readout in Q4 https://gaintherapeutics.wordpress.com/2025/11/16/gain-therapeuticsganx-updated-analyst-reports-with-all-eyes-on-biomarker-readout-in-q4/

GT-02287 addresses multiple potential sources of Parkinson's ($GANX) What’s the first domino in Parkinson’s disease? **Mainstream science points to the lysosome and α-synuclein aggregation—the idea that misfolded α-syn builds up because the lysosomal “trash system” breaks down. But what if that’s not where the problem starts?** The recent Neuroscience poster …

Just opened a position on GANX.

Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days

Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days

Don't miss out on GANX. Im in at 2.85

GANX. Cure/slow for Parkinson’s This is critical: GANX will not move gradually — it will move in violent jumps on news. Q1–Q2 2025 Phase 1b biomarker + functional interim data • Likely price reaction: +20% to +150% if strong • Or –20% to –50% if poor Q3–Q4 2025 Full Phase …

GANX is in the move. Going from 3.60 to 60$+ in next year. Parkinson’s cure.

Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days

Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days Gain Therapeutics will put out their 90 day phase 1b Parkinson’s trial data this month. This data will have 16 patients through the first 90 days of the trial. It will include biomarker data …

GANX December Updated Corporate Deck Getting one last GANX post in before the company rockets out of Pennystock land. I linked the new corporate slide deck. Note in slide 3 the bullet about GT-02287 that reads: “Initial results from Phase 1B suggest GT-02287 has a disease-slowing effect” That bullet statement …